This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

ADEMPAS® (riociguat) dual mode of action

Prescribing Information

Length: 02:43

ADEMPAS is a sGC (soluble guanylate cyclase) stimulator that works on the Nitric Oxide (NO) pathway by stabilising NO-sGC binding and stimulating sGC directly, leading to increased cGMP (cyclic guanosine monophosphate) generation.1

When NO binds to sGC, the enzyme catalyses synthesis of the signalling molecule cGMP. Intracellular cGMP has an important part in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Pulmonary Hypertension is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-sGC-cGMP pathway.1

ADEMPAS has a dual mode of action. It sensitises sGC to endogenous NO by stabilising the NO-sGC binding, it also directly stimulates sGC independently of NO. ADEMPAS restores the NO-sGC-cGMP pathway and leads to increased generation of cGMP. This results in an improvement of pulmonary vascular haemodynamics and an increase in exercise ability.1

More information about ADEMPAS® (riociguat)’s clinical data in Pulmonary Arterial Hypertension:

Reference

  1. ADEMPAS Summary of Product Characteristics.

Supporting documentation

GB-ADE-00265 | Date of Preparation: February 2020